News

Tocilizumab Monotherapy for RA May Suffice in Some

Publish date: December 19, 2011

 

EXPERT ANALYSIS FROM A COURSE SPONSORED BY NEW YORK UNIVERSITY

Dr. Yazici serves as a consultant to Bristol-Myers Squibb and Genentech.

Pages

Recommended Reading

Heart of a Lion: Rheumatologist Holds Fast to His Charitable Plans
MDedge Rheumatology
RA: Adalimumab, MTX Induction Yields Sustained Response
MDedge Rheumatology
Rituximab-Induced Low IgG Linked to Infections
MDedge Rheumatology
Seropositivity Predicts Good Response to Rituximab in RA
MDedge Rheumatology
RA Remission Rates With Tocilizumab Monotherapy Equals Combination TX With Methotrexate*
MDedge Rheumatology
Exploring the Safety of the New Subcutaneous Abatacept
MDedge Rheumatology
Two Biomarkers Predict Response to Rituximab in RA
MDedge Rheumatology
Retreatment With High-Dose Rituximab Reduced DAS28 Levels
MDedge Rheumatology
DMARDs Fail to Enhance Anti-TNF Effects in Spondyloarthritis
MDedge Rheumatology
Questionnaire May Help Tweak RA Treatment Based on Flare
MDedge Rheumatology